Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc

Blood

Volumn 123, Issue 2, 2014, Pages 228-238

  Stoddart, Angela ^a   Wang, Jianghong ^a   Fernald, Anthony A ^a   Karrison, Theodore ^b   Anastasi, John ^b,c   Le Beau, Michelle M ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; APC PROTEIN; CYANOCOBALAMIN; EARLY GROWTH RESPONSE FACTOR 1; ETHYLNITROSOUREA; HEMOGLOBIN; INTRINSIC FACTOR; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN P53;

5Q- SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW DISEASE; CELL VOLUME; CHROMOSOME 5; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROID CELL; EXTRAMEDULLARY HEMATOPOIESIS; FLOW CYTOMETRY; HAPLOINSUFFICIENCY; HEMATOPOIETIC CELL; MACROCYTIC ANEMIA; MONOCYTOSIS; MOUSE; MUTAGENESIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; STROMA CELL; T CELL LYMPHOMA; T LYMPHOCYTE; THERAPY RELATED MYELOID NEOPLASM; ALLELE; ANIMAL; APOPTOSIS; BONE MARROW; CHEMICALLY INDUCED DISORDER; CHROMOSOME DELETION; CYTOLOGY; DRUG EFFECT; ERYTHROBLAST; ERYTHROPOIESIS; GENETICS; GENOTYPE; HETEROZYGOTE; HUMAN; LETHAL GENE; METABOLISM; MORTALITY; PATHOLOGY; SPLEEN; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ALLELES; ANEMIA, MACROCYTIC; ANIMALS; APOPTOSIS; BONE MARROW; CELLULAR MICROENVIRONMENT; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; EARLY GROWTH RESPONSE PROTEIN 1; ERYTHROBLASTS; ERYTHROPOIESIS; ETHYLNITROSOUREA; GENES, LETHAL; GENOTYPE; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMANS; MICE; MICE, TRANSGENIC; SPLEEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897018966     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-506568     Document Type: Article

References (39)

1. Stoddart A, McNerney ME, Bartom E, et al Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis. 2011; 3(1):e2011019.
2. Pedersen-Bjergaard J., Andersen MK, Andersen M.T., Christiansen DH Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008; 22(2): 240-248. (Pubitemid 351250527)
3. Smith SM, Le Beau MM, Huo D, et al Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102(1): 43-52. (Pubitemid 36759634)
4. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012; 30(8): 820-829.
5. Boultwood J, Pellagatti A, McKenzie A.N., Wainscoat JS Advances in the 5q-syndrome. Blood. 2010; 116(26): 5803-5811.
6. Ebert BL. Molecular dissection of the 5q deletion in myelodysplastic syndrome. Semin Oncol. 2011; 38(5): 621-626.
7. Barlow JL, Drynan LF, Hewett D.R., et al A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med. 2010; 16(1): 59-66.
8. Joslin JM, Fernald AA, Tennant T.R., et al Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007; 110(2): 719-726. (Pubitemid 47105411)
9. Pellagatti A, Cazzola M, Giagounidis A.A., et al Gene expression profiles of CD341 cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006; 108(1): 337-345. (Pubitemid 43990647)
10. Wang J, Fernald AA, Anastasi J, Le Beau MM, Qian Z. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood. 2010; 115(17): 3481-3488.
11. Baron V, Adamson ED, Calogero A, Ragona G., Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006; 13(2): 115-124. (Pubitemid 43113412)
12. Min IM, Pietramaggiori G, Kim F.S., Passegué E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell. 2008; 2(4): 380-391. (Pubitemid 351455239)
13. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001; 1(1): 55-67. (Pubitemid 33741881)
14. Luis TC, Naber BA, Roozen P.P., et al Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell. 2011; 9(4): 345-356.
15. Qian Z, Chen L, Fernald A.A., Williams BO, Le Beau MM. A critical role for Apc in hematopoietic stem and progenitor cell survival. J Exp Med. 2008; 205(9): 2163-2175.
16. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy K.M., Kronenberg HM, Scadden DT. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008; 2(3): 274-283. (Pubitemid 351298592)
17. Suda T, Arai F. Wnt signaling in the niche. Cell. 2008; 132(5): 729-730. (Pubitemid 351312805)
18. Wang Y, Krivtsov AV, Sinha A.U., et al The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010; 327(5973): 1650-1653.
19. Kode A, Manavalan S, Mossialou I., et al Leukemogenic Transformation of Hematopoietic Cells by Constitutive Activation of Canonical Wnt Signaling in Osteoblast Precursors. Blood. 2012; 120: 509. [ASH Annual Meeting
20. Lui C, Mills K, Brocardo M.G., Sharma M., Henderson BR APC as a mobile scaffold: regulation and function at the nucleus, centrosomes, and mitochondria. IUBMB Life. 2012; 64(3): 209-214.
21. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001; 19(5): 1405-1413. (Pubitemid 32202547)
22. Shih AH, Chung SS, Dolezal E.K., et al Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013; 98(6): 908-912.
23. Asai T, Liu Y, Bae N., Nimer SD The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J Cell Physiol. 2011; 226(9): 2215-2221.
24. Liu Y, Elf SE, Miyata Y, et al p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009; 4(1): 37-48.
25. Zhao Z, Zuber J, Diaz-Flores E, Lintault L., Kogan SC, Shannon K, Lowe SW p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010; 24(13): 1389-1402.
26. Shibata H, Toyama K, Shioya H., et al Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science. 1997; 278(5335): 120-123.
27. Kühn R., Schwenk F, Aguet M., Rajewsky K. Inducible gene targeting in mice. Science. 1995; 269(5229): 1427-1429.
28. Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc. 2009; 4(1): 102-106.
29. Maeda T, Ito K, Merghoub T., et al LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev Cell. 2009; 17(4): 527-540.
30. Socolovsky M, Nam H, Fleming M.D., Haase VH, Brugnara C, Lodish HF Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001; 98(12): 3261-3273.
31. Yu J, Baron V, Mercola D., Mustelin T, Adamson ED A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ. 2007; 14(3): 436-446.
32. Lane SW, Sykes SM, Al-Shahrour F, et al The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood. 2010; 115(17): 3489-3497.
33. Lane SW, Scadden DT, Gilliland DG The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009; 114(6): 1150-1157.
34. Ximeri M, Galanopoulos A, Klaus M., et al.; Hellenic MDS Study Group. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010; 95(3): 406-414.
35. Greenberger JS, Anderson J, Berry L.A., Epperly M., Cronkite EP, Boggs SS Effects of irradiation of CBA/CA mice on hematopoietic stem cells and stromal cells in long-term bone marrow cultures. Leukemia. 1996; 10(3): 514-527. (Pubitemid 26128794)
36. Hellman S, Botnick L, Mauch P. Stem-cell biology and cancer therapy: the more things change⋯ J Clin Oncol. 2008; 26(6): 821-822. (Pubitemid 351398067)
37. Lorimore SA, Chrystal JA, Robinson J.I., Coates PJ, Wright EG Chromosomal instability in unirradiated hemaopoietic cells induced by macrophages exposed in vivo to ionizing radiation. Cancer Res. 2008; 68(19): 8122-8126.
38. Ayala F, Dewar R, Kieran M., Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia. 2009; 23(12): 2233-2241.
39. Sugrue T, Brown JA, Lowndes N.F., Ceredig R. Multiple facets of the DNA damage response contribute to the radioresistance of mouse mesenchymal stromal cell lines. Stem Cells. 2013; 31(1): 137-145.